Previous 10 | Next 10 |
Dynavax press release ( NASDAQ: DVAX ): Q4 GAAP EPS of $0.45 in-line. Revenue of $184.49M (-5.4% Y/Y) beats by $6.11M . HEPLISAV-B ® vaccine net product revenue of $126 million, representing 104% growth compared to 2021 CpG 1018 ® adjuvant vaccine net...
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance PR Newswire 2022 total revenue of $723 million , up 64% from $439 million in 2021 HEPLISAV-B ® vaccine net product revenue of...
Summary Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality. I look at iShares Genomics Immunology and Healthcare ETF, an ETF in genomics and immunology. 10 stocks cheaper than their peers in Nov...
Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 PR Newswire EMERYVILLE, Calif. , Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceut...
Summary Dynavax has executed its pandemic strategy with finesse. HEPLISAV-B looks to be a gift that keeps on giving for Dynavax. The Dynavax pipeline provides a tense example of past, perfect and future imperfect. What's next is the big question that management will need to addr...
Dynavax ( NASDAQ: DVAX ) said its common stock had been approved for uplisting to the Nasdaq Global Select Market and will continue trading under its current ticker symbol "DVAX." The Nasdaq Global Select Market consists of over 1,700 stocks. Dynavax was previously listed on ...
Dynavax Announces Uplisting to the Nasdaq Global Select Market PR Newswire EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercia...
Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...
-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China -- -- SCB-2019 (CpG 1018/Alum) ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With 2022 in the rearview mirror, it’s time to hunt for solid, undervalued long-term stocks to buy. First, it’s essential to define what is meant by long-term. Secondly, we need to classify what makes a stoc...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing inn...
2024-06-21 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...